drugset
drugset / Trial / NCT05026749

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749 ↗

Phase 3 Recruiting 370 enrolled University of Alabama at Birmingham Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.

Timeline

Start
2022-02-27
Primary completion
2027-07-01
Completion
2028-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 20 mg/kg Intravenous

Indications

respiratory syncytial virus infectious disease